Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Thermo Fisher's sweetened Qiagen bid fails to win over key investor

share with twitter share with LinkedIn share with facebook
07/16/2020 | 11:11am EDT
FILE PHOTO: People carrying a box from ThermoFisher Scientific, a company that produces coronavirus tests, walk outside Downing Street in London

Thermo Fisher Scientific raised its bid for Qiagen by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.

The U.S. laboratory equipment supplier said it had lifted its bid to 43 euros per share from 39 euros, representing a 35% premium to Qiagen's closing price when it made the initial offer on March 2.

The revised offer values Qiagen at 11.3 billion euros and is backed by Qiagen's board.

Thermo Fisher has been under pressure from some Qiagen shareholders to sweeten its bid, particularly after the company said last week it was experiencing strong demand for products related to coronavirus testing.

One of those investors, hedge fund Davidson Kempner, said on Thursday that it would reject the new offer because it still "falls short of fair value". It said a price of between 48 euros and 52 euros a share was more appropriate.

Thermo Fisher Chief Executive Marc N. Casper said that industry conditions had changed considerably in recent months.

"After careful consideration, we've decided to increase our offer for Qiagen to reflect the fair value of the business given the current environment," Casper said in a statement.

Last week, Qiagen beat expectations with a preliminary 18-19% rise in second-quarter sales and a 68% rise in earnings per share amid strong demand for products used in coronavirus testing.

As part of the sweetened offer, Thermo Fisher also reduced the minimum acceptance threshold to 66.67% of outstanding ordinary share capital from 75% and the deadline to vote on the deal has been extended by two weeks until Aug. 10.

(Reporting by Caroline Copley; additional reporting by Alexander Huebner; additional writing by Tom Sims; Editing by David Goodman and Carmel Crimmins)

share with twitter share with LinkedIn share with facebook
Latest news on QIAGEN N.V.
08:00aTHERMO FISHER SCIENTIFIC : Provides Process Overview for the Announcement of Fin..
AQ
08/10QIAGEN N.V. : Preliminary announcement of the publication of financial reports a..
EQ
08/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
08/06Davidson Kempner says again it will not be tendering Qiagen shares
RE
08/06Davidson Kempner says again it will not be tendering Qiagen shares
RE
08/05QIAGEN N.V. : Release of a capital market information
EQ
08/05QIAGEN : 2Q Earnings Snapshot
AQ
08/04QIAGEN : Reports Full Results for Second Quarter and First Half Of 2020
BU
08/03QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
08/03Qiagen investor Davidson Kempner ups stake to 8%
RE
More news
Financials (USD)
Sales 2020 1 774 M - -
Net income 2020 334 M - -
Net Debt 2020 1 037 M - -
P/E ratio 2020 31,8x
Yield 2020 -
Capitalization 11 135 M 11 135 M -
EV / Sales 2020 6,86x
EV / Sales 2021 6,35x
Nbr of Employees 5 200
Free-Float 92,9%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 44,91 $
Last Close Price 48,70 $
Spread / Highest target 2,67%
Spread / Average Target -7,78%
Spread / Lowest Target -34,3%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.44.08%11 135
LONZA GROUP54.81%44 340
CELLTRION, INC.66.85%35 452
IQVIA HOLDINGS INC.3.11%30 471
MODERNA, INC.252.61%27 215
SEATTLE GENETICS, INC.34.33%26 705